Table 4.
Characteristics of all cases with severe COVID-19 from the CHE-IBD cohort
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | Total | |
|---|---|---|---|---|---|---|---|---|---|
| Age (years—IQR) | 76 | 84 | 74 | 65 | 50 | 61 | 84 | 87 | Median 68.5 (62–84) |
| Gender | Male | Male | Male | Male | Male | Male | Male | Male | 100% male |
| COVID-19 confirmation | PCR and X-thx | PCR | PCR | PCR and CT-thx | PCR and CT-thx | PCR and CT-thx | PCR and X-thx | PCR | 100% |
| Symptoms before admission (days-IQR) | 11 | 1 | 1 | 9 | 10 | 12 | 14 | – | Median 7.5 (1–12) |
| Admission (days—IQR) | 4 | 15 | 21 | 11 | 14 | 10 | 10 | – | Median 12.5 (10–15) |
| ICU admission | No | No | No | 5 days | No | No | No | No | 12.5% |
| Respiratory support | No | No | No | Optiflow™ | No | No | No | No | 12.5% |
| COVID-therapy | Dexamethasone cefuroxime | None | Dexamethasone | Dexamethasone tocilizumab | Dexamethasone | Dexamethasone cefuroxime | Dexamethasone | None | Dexamethasone in 75% |
| Outcome COVID-19 | Recovered | Deceased | Recovering | Recovering | Recovering | Recovering | Recovering | Deceased | 25% mortality |
| Comorbidity | None | Dm2, heart failure, macro- and microangiopathy | Dm2 | Dm2, OSAS , hypertension, hypothyroid disease | OSAS | None | Dm2, atrial fibrillation | Ischemic heart failure, pulmonary hypertension | 75% |
| Body Mass Index (kg/m2- IQR) | 23.7 | 29.8 | 25.8 | 28.1 | 31.6 | 23.9 | 24.6 | 28.1 | Median 27.7 (24.1–29.4) |
| IBD type | UC | CD | UC | UC | UC | UC | UC | CD | 75% UC |
| IBD duration (years-IQR) | 32 | 7 | 25 | 50 | 4 | 22 | 7 | 11 | Median 27 (7–30) |
| Worst IBD disease activity (Montreal) | E3S0 | A3L1B3 | E3S2 | E1S0 | E1S2 | E1S0 | E1S0 | A3L1B1 | |
| IBD medication | None | None | None | None | Mesalamine 2 g per os | Thioguanine 20 mg per os | Mesalamine 2 g per os | Budesonide 9 mg orally | 50% no therapy |
| Last IBD check (weeks prior to COVID-19—IQR) | 51 | 8 | 10 | 7 | 1 | 12 | 43 | 2 | Median 26 (3–35) |
| Disease activity at last check | Remission | Remission | Remission | Remission | Mild | Remission | Mild | Mild | 62.5% remission, 37.5% mild |
| Last endoscopy (months prior to COVID-19) | 24 | 36 | 12 | 10 | 1 | 3 | 36 | 30 | Median 18.5 (5–35) |
| Endoscopy outcome | Remission | Remission | Mayo1 | Mayo2 proctitis | Mayo1 proctitis | Remission | Mayo2 proctitis | Remission | 50% in remission |
COVID-19 coronavirus disease 2019; IQR interquartile range 25 to 75%; PCR polymeric chain reaction; X-thx X-ray of the thorax; CT-thx computed tomography of the thorax; ICU intensive care unit; DM2 type 2 diabetes mellitus; OSAS obstructive sleep apnea syndrome; IBD inflammatory bowel disease; UC ulcerative colitis; CD Crohn’s disease; g gram; mg milligram; Montreal: E extension; S symptoms; A age; L luminal disease; B behavior